Thioflavin S (NSC71948) Interferes with Bcl-2-Associated Athanogene (BAG-1)-Mediated Protein-Protein Interactions

Adam Sharp, Simon J. Crabb, Peter W. M. Johnson, Angela Hague, Ramsey Cutress, Paul A. Townsend, A. Ganesan, and Graham Packham

Cancer Research UK Centre, Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, United Kingdom (A.S., P.W.M.J., R.C., G.P.); Department of Oral and Dental Science, University of Bristol, Lower Maudlin Street, Bristol, United Kingdom (A.H.); Division of Human Genetics, University of Southampton School of Medicine, Southampton General Hospital, Southampton, United Kingdom (P.A.T.); and School of Chemistry, University of Southampton, Highfield, Southampton, United Kingdom (A.G.)

Received March 18, 2009; accepted August 17, 2009

ABSTRACT

The C-terminal BAG domain is thought to play a key role in BAG-1-induced survival and proliferation by mediating protein-protein interactions, for example, with heat shock proteins HSC70 and HSP70, and with RAF-1 kinase. Here, we have identified thioflavin S (NSC71948) as a potential small-molecule chemical inhibitor of these interactions. NSC71948 inhibited the interaction of BAG-1 and HSC70 in vitro and decreased BAG-1:HSC70 and BAG-1:HSP70 binding in intact cells. NSC71948 also reduced binding between BAG-1 and RAF-1, but had no effect on the interaction between two unrelated proteins, BIM and MCL-1. NSC71948 functionally reversed the ability of BAG-1 to promote vitamin D3 receptor-mediated transactivation, an activity of BAG-1 that depends on HSC70/HSP70 binding, and reduced phosphorylation of p44/42 mitogen-activate protein kinase. NSC71948 can be used to stain amyloid fibrils; however, structurally related compounds, thioflavin T and BTA-1, had no effect on BAG-1:HSC70 binding, suggesting that structural features important for amyloid fibril binding and inhibition of BAG-1:HSC70 binding may be separable. We demonstrated that NSC71948 inhibited the growth of BAG-1 expressing human ZR-75-1 breast cancer cells and wild-type, but not BAG-1-deficient, mouse embryo fibroblasts. Taken together, these data suggest that NSC71948 may be a useful molecule to investigate the functional significance of BAG-1 C-terminal protein interactions. However, it is important to recognize that NSC71948 may exert additional “off-target” effects. Inhibition of BAG-1 function may be an attractive strategy to inhibit the growth of BAG-1-overexpressing cancers, and further screens of additional compound collections may be warranted.

Bcl-2-associated athanogene (BAG-1) is a multifunctional protein that interacts with multiple cellular targets and modulates a wide range of cellular processes (Townsend et al. 2003b). Overexpression of BAG-1 protects cells from many apoptotic stimuli, promotes autophagy, enhances proliferation and metastasis, and modulates the transcriptional activity of a variety of nuclear hormone receptors (NHRs) (Townsend et al., 2003b; Gurusamy et al., 2009). BAG-1 is essential for differentiation and survival of hematopoietic and neuronal cells (Götz et al., 2005). Functional and expression studies suggest that overexpression of BAG-1 may play an important role in diverse cancer types (Townsend et al., 2003b). BAG-1 is frequently overexpressed in cancer and can correlate with important clinical parameters (Cutress et al., 2003; Millar et al., 2009). Depletion of BAG-1 by small interfering RNA (siRNA) is sufficient to promote apoptosis in colorectal carcinoma cells (Clemo et al., 2008), and overexpression of a dominant negative form of BAG-1 decreases cell growth of breast cancer cells in vitro and in vivo (Kudoh et al., 2002). Antisense or siRNA-mediated depletion of BAG-1 is warranted.

This work was supported by the Biotechnology and Biological Sciences Research Council [Grant BB/C005783/1]; and the Breast Cancer Campaign and Cancer Research UK [Grant C2750/A2740]. Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.109.153801.

ABBREVIATIONS: BAG-1, Bcl-2 associated athanogene; ABT-737, N-[4-(4-[4-(4-chloro-biphenyl-2-ylmethyl]-piperazin-1-yl)-benzoyl]-4-(3-dimethylamino-1-phenylsulfanylphenyl-propylamino)-3-nitro-benzenesulfonamide. BTA-1, 2-(4-[methylaminophenyl]benzothiazole; CHIP, carboxy terminus of Hsc70 interacting protein; ERK1/2, extracellular signal-regulated kinase 1/2; NHR, nuclear hormone receptors; NCI-DTP, National Cancer Institute Developmental Therapeutics Program; DMEM, Dulbecco’s modified Eagle’s medium; FCS, fetal calf serum; MEF, mouse embryo fibroblast; GST, glutathione S-transferase; PBS, phosphate-buffered saline; BSA, bovine serum albumin; siRNA, small interfering RNA; VDR, vitamin D receptor; NLS, nuclear localization sequence; ULD, ubiquitin-like domain; thioflavin T, 4-(3,6-dimethyl-1,3-benzothiazol-2-yI)-N,N-dimethylaniline chloride.
also decreases cell growth and sensitizes to staurosporine or paclitaxel in HeLa cells (Takahashi et al., 2003; Xiong et al., 2003). BAG-1 haploinsufficiency impairs lung tumorigenesis (Götz et al., 2004). More recent findings have implicated BAG-1 in brain function and neurological disorders, where overexpression protects neuronal cells from staurosporine and thapsigargin and ameliorates motor defects in a mouse model of Huntington disease (Liman et al., 2005; Orr et al., 2008). BAG-1 is also a target for mood stabilizers and regulates recovery from manic-like and depression-like behavior (Maeng et al., 2008).

In human cells, BAG-1 exists as three major isoforms (BAG-1S, BAG-1M, and BAG-1L; Fig. 1A) derived by alternate translation initiation from a single mRNA. All BAG-1 isoforms contain a C-terminal, evolutionary conserved BAG domain (Takayama et al., 1999) and a central ubiquitin-like domain. The larger isoforms (M and L) have unique N-terminal extensions. The functional significance of these variable N-terminal regions is poorly understood. BAG-1L possesses a nuclear localization sequence and is a predominant nuclear protein, whereas the other isoforms partition between the cytoplasm and nucleus.

The C-terminal BAG domain comprises a bundle of three α-helices, of which helices 2 and 3 mediate electrostatic interactions of BAG-1 with subdomains IB and IIB of the ATPase domain of the 70-kDa heat shock proteins, HSC70 and HSP70 (Briknarova et al., 2001; Sondermann et al., 2001). Although helix 1 is not directly involved in binding, it may contribute to intramolecular interactions that stabilize the overall structure of the BAG domain. BAG-1 acts as a cochaperone and stimulates nucleotide exchange of HSC70/HSP70 (Briknarova et al., 2001; Sondermann et al., 2001). Although helix 1 is not directly involved in binding, it may contribute to intramolecular interactions that stabilize the overall structure of the BAG domain. BAG-1 interacts with a nuclear localization sequence and is a predominant nuclear protein, whereas the other isoforms partition between the cytoplasm and nucleus.

HSC70 and HSP70 play important roles in multiple cell processes, via effects on protein (re)folding and degradation, and expression and activity of NHR (Mayer and Bukau, 2005). BAG-1 binding to these multifunctional proteins may explain, at least in part, the multiple effects associated with BAG-1 overexpression. The BAG-1 ULD is required for the interaction of BAG-1 with the proteasome (Lüders et al., 2000), and BAG-1 may act to coordinate the function of chaperones and the proteasome in the degradation of specific target proteins (Arndt et al., 2007). Thus, BAG-1 can interact simultaneously with HSC70 and the proteasome (Lüders et al., 2000; Alberti et al., 2002), and its ability to influence chaperone function may facilitate the unloading of chaperone clients in the vicinity of the proteasome to enhance degradation. BAG-1 also interacts with CHIP, an E3 ubiquitin ligase that plays a key role in protein triage (i.e., degradation versus refolding) decisions (McDonough and Patterson, 2003). BAG-1 and CHIP cooperate to target the glucocorticoid receptor for proteasomal degradation (Demand et al., 2001). Conversely, overexpression of BAG-1 has been shown to decrease proteasomal degradation of Tau (Elliott et al., 2007).

Functional studies demonstrate that BAG-1 isoforms can promote the survival and proliferation of various cell types in vitro and in vivo. Mutational analysis demonstrates that suppression of apoptosis and regulation of NHR function is dependent on interaction with HSC70/HSP70 via the C-terminal BAG domain (Townsend et al., 2003b; Townsend et al., 2004). These data suggest that inhibition of the interaction between BAG-1 and HSC70/HSP70 by small chemical com-
Compounds is an attractive strategy to counter BAG-1 function. The aim of this work was to identify small molecule inhibitors of the BAG-1:HSC70 interaction.

Materials and Methods

Cell Culture and Plasmids

MCF7 and ZR-75-1 human breast cancer cells, and BAG-1-deficient and wild-type mouse embryo fibroblasts (MEFs) (kind gifts of S. Weise, Ruhr-University, Germany) (Götz et al., 2005) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal calf serum (FCS) (PAA Laboratories, Yeovil, United Kingdom) and penicillin and streptomycin (Invitrogen). H376 oral squamous carcinoma cells were cultured in DMEM: Ham's F-12 (1:1) Nutrient Mix medium (Invitrogen) containing 10% (v/v) FCS, 2 mM l-glutamine, and 0.5 μg/ml hydrocortisone. To produce stable clones overexpressing human BAG-1S, MCF7 cells were transfected with pcDNA3-BAG-1S expression construct (Townsend et al., 2003a) or empty pcDNA3 vector (Invitrogen) by use of calcium phosphate precipitation followed by single-cell cloning in the presence of G418. Wild-type BAG-1L and the BAG-1L H2 mutant (which has two point mutations within helix 2: E283A, K287A) were expressed by use of pcDNA3-derived plasmids (Townsend et al., 2003a; Lee et al., 2007). The luciferase reporter plasmid (DR3)tkLUC was derived from the rat atrial natriuretic factor gene promoter and was a kind gift of Prof Carsten Carlberg (Department of Biochemistry, University of Kuopio, Finland).

Compounds

The mechanistic, diversity, challenge set and natural product compound collections were obtained from National Cancer Institute Developmental Therapeutics Program (NCI-DTP) [National Cancer Institute, Rockville, MD, (http://dtp.cancer.gov)]. Refills of selected compounds were also obtained from NCI-DTP and stored as 100 mM stocks in DMSO at −20°C. Thioflavin S, thioflavin T, and BTA-1 were obtained from Sigma Chemical (Poole, Dorset, UK). For experiments using MEFs, thioflavin S was prepared as a 10 mM stock in complete DMEM on the day of use.

BAG-1:HSC70 in Vitro Interaction Assay

Glutathione S-transferase (GST) and GST-BAG-1S were purified by use of glutathione-Sepharose beads (GE Healthcare, Little Chalfont, Buckinghamshire, UK) from b212 Escherichia coli transformed with pGEX-2TK (GE Healthcare) or pGEX-BAG-1S as described previously (Brimmell et al., 1999). Wells of a 96-well plate were incubated overnight at 4°C with 10 ng of recombinant HSC70 (Cambridge BioScience, Cambridge, UK) in 100 μl of phosphate-buffered saline (PBS). The wells were washed three times with PBS, and GST or GST-BAG-1S (each 500 ng) was added. The plates were incubated for a further 20 min at room temperature. Unbound GST proteins were removed by washing in PBS. The 3.10 G3E2 BAG-1 specific monoclonal antibody (Brimmell et al., 1999; 1:1000 dilution of ascites in PBS) was added to the wells (200 μl/well) and incubated for 1 h at room temperature. Wells were washed, and 200 μl of horseradish peroxidase-conjugated anti-mouse immunoglobulin antibody (GE Healthcare) diluted (1:5000) in PBS was added to the wells and incubated for 1 h at room temperature. Wells were washed, and 200 μl of o-phenylenediamine substrate (Sigma Chemical) was added. The plate was incubated at 37°C for 10 min, and absorbance at 450 nm was measured with use of a plate reader. To test the ability of compounds to inhibit the BAG-1:HSC70 interaction, compounds were diluted in PBS and added to HSC70-coated wells for 4 h before the addition of GST-BAG-1S. The absorbance of wells with GST-BAG-1S and HSC70 (with no test compound present) was set at 100% interaction, and the absorbance of wells containing GST and HSC70 was set at 0%.

Counterscreens

Antibody Counterscreen. To investigate whether compounds interfered with detection of BAG-1S, we measured the ability of compounds to interfere with detection of BAG-1S by the 3.10 G3E2 monoclonal antibody (Brimmell et al., 1999). Wells of a 96-well plate were incubated overnight at 4°C with 500 ng of recombinant GST-BAG-1S in 100 μl of PBS. The wells were washed three times in a bath of PBS, and nonspecific binding sites were blocked by incubation with PBS containing 1% (v/v) bovine serum albumin (BSA) (Sigma Chemical) for 1 h at room temperature. Compounds were added to the wells and incubated at room temperature for 4 h. The wells were washed in PBS, and 3.10 G3E2 BAG-1-specific monoclonal antibody (1:1000 dilution of ascites in PBS) was added to the wells (200 μl/well) and incubated for 1 h at room temperature. Bound antibody was detected as described above.

Luciferase Activity. Compounds were incubated with purified luciferase (Sigma Chemical) (100 ng in 20 μl of luciferase lysis buffer; Promega, Southampton, UK). After 5 min, luciferase activity was detected after the addition of 100 μl of luciferase assay reagent (Promega) according to the manufacturer's instructions. Control luciferase assays were performed in the absence of compound.

BSA Counterscreen. To identify compounds with high nonspecific protein-binding activity, we determined whether excess BSA interfered with the ability of compounds to interfere with BAG-1: HSC70 binding in the in vitro binding assay. The assay was performed as described above with the addition of BSA (0.1 mg/ml) to all buffers.

Interaction in Cells

BAG-1S:HSC70/HSP70. To analyze the interaction of BAG-1 and endogenous HSC70/HSP70, MCF7 cells overexpressing BAG-1 (Clone BAG-1S D) were plated in medium containing serum and left to adhere for 4 to 5 h. Cells were then treated with compounds and were cultured for a further 16 h. Cells were resuspended in HMKEN buffer [10 mM HEPES, pH 7.2, 5 mM MgCl2, 142 mM KCl, 2 mM EGTA, 0.2% (v/v) Nonidet P40, 1:100 protease inhibitor cocktail (Sigma Chemical)] by trituration through a 21-gauge needle, lysed on ice for 30 min, and clarified by centrifugation (13,000 rpm for 30 min). One-thirtieth of the lysate was retained as a whole-cell lysate. The remaining sample was preclarified by use of protein G-Sepharose beads for 30 min at 4°C. Protein G-Sepharose beads were washed by centrifugation. Lysates were incubated with the BAG-1-specific rabbit polyclonal antibody, TB3 (Brimmell et al., 1999) (5 μl per 1400 μl lysate), at 4°C for 16 h to analyze the interaction between BAG-1 and HSC70/HSP70. A further lysate was incubated with preimmune control serum (5 μl per 900 μl lysate) to control for nonspecific interactions. The immune complexes were incubated with protein G-Sepharose beads for 4 to 6 h and removed by centrifugation. The beads were washed five times by use of HMKEN buffer, resuspended in SDS-polyacrylamide gel electrophoresis sample buffer, and heated at 95°C for 5 min. Immunoblotting was performed as described previously (Packham et al., 1997). Primary antibodies used were 3.10 G3E2 hybridoma supernatant (Brimmell et al., 1999) for BAG-1, B6 (Santa Cruz Biotechnology, Santa Cruz, CA) for HSC70 and C92F3A5 (Cambridge BioScience) for HSP70.

MCL-1-BIM. To analyze interaction of MCL-1 and BIM, MCF7 cells were plated in medium containing serum and left to adhere for 4 to 5 h. Cells were then treated with compound and were cultured for a further 16 h. Cells were resuspended in MCL-1-BIM coimmunoprecipitation buffer (142.5 mM KCl, 5 mM MgCl2, 20 mM Tris, pH 7.4, 1 mM EGTA, 0.2% (v/v) Nonidet P40), vortexed, lysed on ice for 30 min, and clarified by centrifugation (13,000 rpm for 30 min). One-tenth of the lysate was retained as a whole-cell lysate. The remaining sample was preclarified by use of protein G-Sepharose beads for 30 min at 4°C. Proteins G-Sepharose beads were removed by centrifugation. Lysates were incubated with the MCL-1-specific antibody (S19; Santa Cruz Biotechnology) (5 μl per 450 μl lysate) at 4°C
for 16 h to analyze the interaction between MCL-1 and BIM. A further lysate was incubated with the epidermal growth factor receptor specific antibody (1005; Santa Cruz Biotechnology) (5 µl per 450 µl lysate) to control for nonspecific interactions. The immune complexes were incubated with protein G-Sepharose beads for 4 to 6 h and removed by centrifugation. The beads were washed five times with use of MCL-1-BIM coimmunoprecipitation buffer, resuspended in SDS-polyacrylamide gel electrophoresis sample buffer, and heated at 95°C for 5 min. Immunoblotting was performed as described previously (Packham et al., 1997). The primary antibodies used were S9 for MCL-1 and H-191 for BIM-1 (both from Santa Cruz Biotechnology).

**Transcription Reporter Assays for Vitamin D Receptor**

To determine the effects of compounds on the potentiation of the vitamin D receptor (VDR) by BAG-1L (Lee et al., 2007), H376 cells were plated at a density of 5000 in a 24-well plate. Cells were transfected 2 days later with (DR3)tkLuc, and pcDNA3 BAG-1L, pcDNA3 BAG-1L-H2, or pCDNA3 control (Invitrogen) with use of Fugene 6 reagent (Roche, Lewes, UK). Cells were also transfected with pRL-tk-luc (Promega) to act as an internal control for transfection efficiency. After transfection, cells were treated with 1,25-dihydroxyvitamin D3 at a concentration of 0.1 µM, or DMSO as a control. After 24 h, firefly and renilla luciferase activity was measured by use of the Dual Luciferase Assay System (Promega) according to the manufacturer’s instructions. Results were analyzed as firefly luciferase activity divided by renilla luciferase activity to control for intersampling variations in transfection activity and cell number.

**Effects of Compounds on ERK1/2 Phosphorylation**

To determine the effect of compounds on ERK1/2 phosphorylation in MCF7 cells, cells were plated at a density of 2 × 10⁵ cells in a 90-mm dish and incubated for 24 h before treatment with various concentrations of compounds. Cells were treated with compounds for 2 h before being harvested and radioimmunoprecipitation assay cell lysates being prepared. Cell lysates were normalized for protein concentration and samples were analyzed by Western blotting as described previously (Packham et al., 1997). Primary antibodies used were 9101 (Cell Signaling Technology, Danvers, MA) for T202/Y204 phosphorylated ERK1/2, 9102 (Cell Signaling Technology, Danvers, MA) for T202/Y204 phosphorylated ERK1/2, 9102 (Cell Signaling Technology) for total ERK1/2 and PC10 (Cancer Research UK Research Services, London, UK) for proliferating cell nuclear antigen.

**Cell Growth Assays**

To measure growth inhibition, cells were plated at a density of 5000 cells per well of a 96-well plate. The next day, cells were treated with various concentrations of compounds. After 6 (for MCF7 or ZR-75-1 cells) or 3 (for MEFs) days, media were removed from each well and replaced with 200 µl of RPMI 1640 medium (Invitrogen) supplemented with 10% (v/v) FCS and 1% (v/v) penicillin/streptomycin/glutamine. CellTiter 96 AQueous One Solution Reagent (20 µl; Promega) was added to the wells, and the plate was incubated at 37°C for 1 to 4 h. Absorbance at 490 nm was measured by use of a Dynatech MR 5000 plate reader (Dynex Technologies, Chantilly, VA).

**Results**

**Identification of NSC71948 as an Inhibitor of the BAG-1:HSC70 Interaction.** To identify potential chemical inhibitors of the BAG-1:HSC70 interaction, we screened the NCI-DTP mechanistic, diversity, natural product, and challenge sets with use of an in vitro BAG-1:HSC70-binding assay (Fig. 1B). We first screened the BAG-1:HSC70 interaction assay by use of the NCI-DTP discovery, natural product, and challenge sets by use of a 100 µM screening concentration and an activity cutoff of ≥70% inhibition to identify putative hits. We identified 12 compounds in this initial screen; however, two of these showed no activity in subsequent IC₅₀ determinations. We also screened the mechanistic set by use of a 10 µM screening concentration and an activity cutoff of ≥50% inhibition. This identified six further hits, all of which demonstrated activity in subsequent IC₅₀ determinations. Thus, from the 3156 compounds screened, we identified 16 confirmed hits (Fig. 1C). We obtained additional samples of the 12 most active compounds from the NCI-DTP and retested their activity in the same interaction assay. With the exception of NSC65828 and NSC652174, these compounds demonstrated inhibition of BAG-1:HSC70 binding. However, the activity of the second batch of compounds was less than that observed with the original compound collections.

A series of counterscreens were performed to exclude false positives or compounds with poor selectivity (Table 1). To determine whether the compounds interfered with the immunodetection system we investigated whether compounds inhibited direct detection of BAG-1S in an enzyme-linked immunosorbent assay-type assay (antibody counterscreen). NSC119911 significantly inhibited direct detection of BAG-1S (IC₅₀ = 37 ± 11 µM) and was therefore excluded from further study. Two further counterscreens were performed to exclude chemical compounds (“frequent hitters”) that seem active in many assays because of nonselective inhibitory activity, for example, by nonselective protein binding and/or aggregation (McGovern et al., 2002); a luciferase assay and addition of excess of BSA to the BAG-1:HSC70-binding assay. Selective compounds would not be expected to inhibit luciferase activity, and their ability to inhibit BAG-1:HSC70 binding should not be significantly affected by BSA. For these assays, compounds were analyzed at approximately twice the IC₅₀ for inhibition of BAG-1:HSC70 binding. The majority of the compounds tested showed a large degree of nonselectivity in at least one of the assays (i.e., >50% inhibition of luciferase activity or direct GST-BAG-1S detection, or >50% loss of activity in the presence of excess BSA) and were therefore excluded from further study. Only one compound, NSC71948, was considered

**TABLE 1**

Results from counterscreens

This is a summary of the results obtained with the indicated compounds (refilled compounds) in the three counterscreen assays. "*" indicates compound was considered active in relevant assay (i.e., >50% inhibition of luciferase activity or direct GST-BAG-1S detection, or >50% loss of activity in the presence of BSA).

<table>
<thead>
<tr>
<th>Compound</th>
<th>Direct GST-BAG-1S Detectiona</th>
<th>Luciferaseb</th>
<th>BSAb</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSC638352</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>NSC71948</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>NSC85561</td>
<td>−</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>NSC73413</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>NSC76027</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>NSC59265</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>NSC7333</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>NSC7223</td>
<td>−</td>
<td>−</td>
<td>NDc</td>
</tr>
<tr>
<td>NSC119911</td>
<td>+</td>
<td>NDd</td>
<td>+</td>
</tr>
<tr>
<td>NSC119913</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
</tbody>
</table>

a Inhibition of direct immunodetection of GST-BAG-1S.

b Inhibition of luciferase activity.

c Inhibition of activity in the BAG-1:HSC70 interaction assay by BSA. For effects on direct detection of GST-BAG-1S, compounds were tested at 100 µM. For effects in the luciferase and BSA assays, compounds were tested at approximately two times their IC₅₀ for inhibition of BAG-1S:HSC70 in vitro binding.
d ND, not determined.
We also analyzed the effect of NSC71948 on the interaction of BAG-1 or its ability to be immunoprecipitated with HSC70 and HSP70 by 50 to 60% but had no effect on expression of BAG-1 or its ability to be immunoprecipitated with the anti-BAG-1 antibody (Fig. 3, A and B). The inhibition of luciferase activity (mean ± S.D.) in the presence of BSA and are derived from two separate experiments, each performed in duplicate. B, BSA counterscreen. The luciferase activity derived from two independent experiments each performed in duplicate. D, BSA counterscreen. The ability of NSC71948 (30 μM) or NSC73413 (15 μM) to inhibit in vitro BAG-1:HSC70 binding was measured in the presence or absence of excess (0.1 mg/ml) BSA. Data shown are remaining activity (mean ± S.D.) in the presence of BSA and are derived from two separate experiments, each performed in duplicate.

**Fig. 2.** Identification of NSC71948 as an inhibitor of the in vitro BAG-1:HSC70 interaction. A, structure of NSC71948 (thioflavin S). B, inhibition of the in vitro BAG-1:HSC70 interaction by NSC71948. The experiment shows the mean of duplicate determinations (± S.D.) of BAG-1:HSC70 interaction in the presence of the indicated concentrations of NSC71948 (refilled stock). Experiment is representative of two independent experiments. C, luciferase counterscreen. The activity of recombinant luciferase was measured in the presence of NSC71948 or NSC119913 (both at 30 μM). The luciferase activity in the absence of added compound was set at 100%. Data shown are mean (± S.D.) luciferase activity derived from two separate experiments, each performed in duplicate.

**Fig. 3.** Effect of NSC71948 on BAG-1:HSC70/HSP70 binding in intact MCF7 cells. A, MCF7-BAG-1S cells were incubated with 100 μM NSC71948, or left untreated as a control. Immunoprecipitations were performed by use of BAG-1-specific antibody TB3 from cells cultured in the presence or absence of NSC71948, or with control preimmune sera (PI). BAG-1S, HSC70, and HSP70 were analyzed by immunoblotting. B, the amounts of BAG-1-bound HSC70 and HSP70 were quantified by digital imaging. The graph shows the interaction of BAG-1 and HSC70 or HSP70 in the presence NSC71948. The level of binding in the absence of NSC71948 was used to set the 100% value. Data are mean (± S.D.) binding derived from two independent experiments each performed in duplicate. *p < 0.05 compared with untreated cells (Student’s t test). C, MCF7 cells were incubated with 100 μM NSC71948, or left untreated as a control, and the binding of MCL-1 and BIM determined by coimmunoprecipitation. The amount of MCL-1-bound BIM was determined by digital imaging and was set at 100% in control cells. The graph shows mean (± S.D.) MCL-1:BIM binding in the presence or absence of NSC71948. The data are derived from two independent experiments, each performed in duplicate.
NSC71948 Interferes with BAG-1-Mediated Potentiation of Vitamin D3 Receptor Activity. BAG-1L potentiates the activity of the VDR via an HSC70/HSP70-dependent mechanism (Lee et al., 2007). Because NSC71948 interferes with BAG-1:HSC70/HSP70 binding in cells, we determined whether NSC71948 suppressed BAG-1-mediated potentiation of the VDR. In control H376 cells without BAG-1L overexpression, vitamin D3 modestly increased luciferase gene expression from a vitamin D3-responsive reporter construct (Fig. 4A). As reported previously (Lee et al., 2007), the activity of the reporter construct was significantly enhanced by overexpression of wild-type BAG-1L, but was unaffected by BAG-1L<sup>H2</sup> which is deficient in HSC70/HSP70 binding (Lee et al., 2007). It is noteworthy that NSC71948 interfered with BAG-1L activity in a dose-dependent manner, reducing BAG-1L activity almost to that of the vector-only control at 50 µM. NSC71948 did not alter the levels of BAG-1L overexpression in H376 cells (Fig. 4B). NSC119913, which did not interfere with BAG-1:HSC70 binding, did not affect BAG-1L-mediated VDR potentiation (data not shown).

NSC71948 Interferes with ERK1/2 Activation. Previous studies have demonstrated that BAG-1 activates RAF-1, and we therefore determined the effect of NSC71948 on this interaction. The RAF-1 interaction was decreased by approximately 50% in NSC71948-treated cells compared with DMSO-treated cells, but was not affected by NSC119913 treatment (Fig. 5C). However, a modest reduction in RAF-1 binding was observed compared with the decrease in ERK1/2 phosphorylation.

Growth Inhibitory Activity of NSC71948. We treated ZR-75-1 breast cancer cells with NSC71948 or NSC119913 (both 50 µM) and determined their effect on cell proliferation (Fig. 6A). ZR-75-1 cells were selected for these studies because they express relatively high levels of BAG-1 compared with other breast cancer cell lines, and both overexpression and dominant negative experiments have suggested that BAG-1 plays an important role in the proliferation and survival of these cells (Brimmel et al., 1999; Kudoh et al., 2002). Whereas control cells reached confluence within 3 days, NSC71948 significantly decreased the rate of cell growth in ZR-75-1 cells. NSC119913 had no effect on cell growth. When measured in 6-day growth inhibition assays (Fig. 6B), the mean IC<sub>50</sub> for NSC71948 was 19 ± 6 µM (mean derived from...
three independent experiments, each performed in triplicate \( \pm \) S.D.). DMSO control-treated cells showed some growth inhibition in this assay at higher concentrations, but NSC119913 did not increase cell growth inhibition at any concentration relative to DMSO.

We also investigated the effects of NSC71948 on wild-type and BAG-1-deficient MEFs (Götz et al., 2005). Wild-type MEFs were relatively resistant to growth inhibitory effects of NSC71948 compared with human ZR-75-1 breast cancer cells. The growth of wild-type MEFs was reduced when cells were treated with 200 or 400 \( \mu \)M NSC71948 compared with controls, but we were unable to define an IC\(_{50}\) in these cells because growth inhibition did not exceed 50\% at any concentration tested (Fig. 6C). By contrast, NSC71948 did not inhibit the growth of BAG-1-deficient MEFs at these concentrations. In fact, the growth of these cells was modestly enhanced by NSC71948. These experiments were performed by use of NSC71948 stocks prepared with complete growth medium to avoid potential effects of DMSO at these higher compound concentrations. However, we were unable to test higher concentrations because of problems with poor solubility.

**Effects of Structurally Related Compounds.** These data demonstrate that NSC71948 interferes with BAG-1 protein interactions. NSC71948 shows some selectivity toward the BAG-1:HSC70 interaction because it did not inhibit MCL-1:BIM binding in intact cells and was not active in any of the in vitro counterscreens. However, NSC71948 can be used as a stain to identify amyloid fibrils (Guntern et al., 1992) and is not therefore entirely specific for BAG-1:HSC70. Binding of NSC71948 to amyloid fibrils is thought to depend on interaction with \( \beta \)-sheets within amyloid proteins. Neither BAG-1 nor HSC70 contain \( \beta \)-sheet structures, suggesting that the effects of NSC71948 on these interactions may be mediated by structural features that are distinct from those required for binding to amyloid fibrils. To investigate the relationship between amyloid binding and inhibition of BAG-1:HSC70 binding, we analyzed the activity of a small series of structurally related proteins that can also be used to stain amyloid fibrils. We analyzed thioflavin T and BTA-1, an uncharged analog of thioflavin T (Fig. 7A). BTA-1, has a higher affinity for binding to A\(_{\beta}(1–40)\) amyloid fibrils than thioflavin T (\( K_{i} 20 \) versus 890 nM) (Klunk et al., 2001). In these assays we also tested the effects of thioflavin S (from Sigma Chemical).

We first compared the effects of the compounds on in vitro interaction of BAG-1 with HSC70 (Fig. 7B). As before, binding was inhibited by NSC71948, with similar results obtained by use of an independent supply of thioflavin S. In contrast, the BAG-1:HSC70 interaction was completely unaffected by thioflavin T or BTA-1 at concentrations up to 100 \( \mu \)M. We also tested the effects of the compounds on ERK1/2 phosphorylation (Fig. 7C and D). As before, NSC71948 (and the additional stock of thioflavin S) effectively decreased phosphorylation of ERK1/2. ERK1/2 phosphorylation was completely unaffected by BTA-1, even though BTA-1 would be expected to enter cells more readily than thioflavins.
addition thioflavin T modestly decreased ERK1/2 phosphorylation by approximately 50%. Finally, we tested the effects of the compounds on ZR-75-1 cell growth (Fig. 7E). BTA-1 (IC\textsubscript{50} 19 ± 1.4 μM; mean derived from three independent experiments each performed in triplicate ± S.D.) inhibited the growth of ZR-75-1 breast cancer cells in a manner similar to NSC71948 (40 ± 1.0 μM); however, thioflavin T showed potent growth inhibitory effects (IC\textsubscript{50} 1 ± 0.6 μM).

**Discussion**

Overexpression of BAG-1 enhances survival and proliferation in many cell lineages including primary cardiac myocytes, neuronal cells, and multiple cancer cell types. Moreover, BAG-1 is essential for the survival of hematopoietic and neuronal cells in vivo (Götz et al., 2005). Several studies have demonstrated that reducing expression or function of BAG-1 (by siRNA, antisense of overexpression of a dominant negative mutant) is sufficient to promote apoptosis and/or growth inhibition (Kudoh et al., 2002; Takahashi et al., 2003; Xiong et al., 2003; Clemo et al., 2008). Although the molecular mechanism of how BAG-1 promotes proliferation and survival of such a diverse range of cell types remains to be uncovered, overexpression studies have demonstrated that this activity frequently requires the C-terminal BAG domain that acts as a docking site for various proteins, including RAF-1, HSC70, HSP70, and CHIP. Therefore, chemical inhibitors of BAG-1 C-terminal protein binding would be valuable tools to investigate the functional significance of these interactions for endogenous BAG-1 and potentially as leads for the development of new therapeutics to interfere with BAG-1-mediated regulation of survival and NHR function in malignant cells.
Our work has taken the first steps toward the identification of chemical probes to investigate BAG-1 protein interactions. In general, protein-protein interactions are considered challenging targets for the development of small-molecule inhibitors, although there are some notable exceptions, such as ABT-737, which prevents interaction between pro-survival Bcl-2 family proteins and their pro-apoptotic BH3-only binding partners. In addition to these studies of small chemical inhibitors, we have also analyzed the activity of a series of overlapping peptides derived from the BAG domain to interfere with BAG-1:HSC70 binding (submitted for publication). We identified a relatively small peptide (12 amino acids) derived from helix 2 of the BAG domain that was sufficient to bind HSC70 and block the BAG-1:HSC70 interaction. This suggests that there may be discrete “hot spots” on BAG-1 that play critical roles in mediating the interaction with HSC70/HSP70, consistent with the idea that the interactions may be inhibited by small chemical compounds.

We identified NSC71948 as a potent and potentially selective inhibitor of BAG-1 C-terminal interactions. NSC71948 inhibited BAG-1:HSC70 binding in vitro but promisingly did not show activity in any of the counterscreens. Moreover, NSC71948 inhibited binding of BAG-1 to HSC70/HSP70 and RAF-1 in intact cells, but had little effect on binding of two unrelated proteins. NSC71948 also interfered with the ability of BAG-1 to enhance transcriptional activation by vitamin D3, an activity that depends on C-terminal interactions (Lee et al., 2007) and decreased ERK1/2 phosphorylation, a downstream target of RAF-1. Because NSC71948 interfered with binding of BAG-1 to HSC70/HSP70 and RAF-1, we predict that it may interact directly with BAG-1. The binding site for NSC71948 may lie within helix 2 that is required for the interaction with both HSC70/HSP70 and RAF-1 (Brikanova et al., 2001; Sondermann et al., 2001; Song et al., 2001). Alternatively, NSC71948 may bind elsewhere within BAG-1 and elicit a conformational change in the BAG domain leading to loss of binding of multiple interaction partners.

Selectivity is a major concern with any chemical inhibitor. Indeed, the majority of the confirmed “hits” identified in primary screening were either false positives (i.e., they interfered with direct BAG-1:S immunodetection) or seemed to act nonselectively (because they inhibited luciferase activity and/or their activity was significantly repressed by excess BSA). Although we have demonstrated a degree of selectivity for NSC71948 in its effects on BAG-1 interactions by use of both in vitro and cell based assays, it is important to recognize the clear potential for additional off-target effects. NSC71948 binds amyloid fibrils which demonstrates interaction with other protein targets; therefore, we analyzed structurally related compounds that stain amyloid fibrils to explore the potential structure features that mediate these effects. In particular, BTA-1 binds to Aβ(1–40) approximately 50-fold more effectively than thioflavin T (Klunk et al., 2001). However, neither thioflavin T nor BTA-1 interfered with BAG-1:HSC70 binding in vitro, suggesting that the structural features of these molecules important for amyloid fibril binding are distinct from those of NSC71948 required for inhibition of BAG-1:HSC70 binding. Thus, it may be possible to synthesize NSC71948/thioflavin S-like molecules with enhanced BAG-1 binding activity and decreased binding to other targets.

In addition to its effects on VDR function and RAF-1 signaling, NSC71948 inhibited the growth of BAG-1 expressing ZR-75-1 human breast cancer cells. These results are consistent with previous studies demonstrating that BAG-1 is required for optimal cell proliferation and survival (Kudoh et al., 2002; Takahashi et al., 2003; Xiong et al., 2003; Götz et al., 2005; Clemo et al., 2008). To directly investigate the role of BAG-1 in mediating the growth inhibitory effects of NSC71948, we analyzed the effects of NSC71948 in wild-type and BAG-1-deficient MEFs. The growth of BAG-1-deficient MEFs was reduced compared with wild-type cells, consistent with the idea that endogenous levels of BAG-1 are required for optimal proliferation in these cells (data not shown). Moreover, NSC71948 inhibited the growth of wild-type, but not BAG-1-deficient MEFs. These results suggest that the growth inhibitory effects of NSC71948 are mediated, at least in part, via inactivation of BAG-1, although they do not discriminate whether these effects are due to inhibition of HSC70/HSP70 or RAF-1 function. We were surprised to find that the growth of BAG-1-deficient cells was modestly enhanced by NSC71948. This effect is clearly independent of BAG-1. However, the BAG domain is present in five distinct human proteins (Takayama and Reed, 2001), at least some of which also interact with HSC70/HSP70 and modulate cell growth/survival (Wang et al., 2008). Thus, NSC71948 may exert effects on other BAG proteins. Alternatively, this effect may reflect nonspecific activity, independent of BAG family proteins.

Despite these encouraging data, it is very important to recognize that the specificity of NSC71948 remains incompletely defined, and growth inhibitory effects may be only partially related to any effects on BAG-1. Indeed, thioflavin T demonstrated potent growth inhibitory activity, whereas effects on ERK1/2 phosphorylation were modest and it did not inhibit BAG-1:HSC70 binding. Presumably, the growth inhibitory effects of thioflavin T are exerted via an alternate pathway. In addition, BTA-1 induced growth inhibition to the same extent as NSC71984, although it did not alter BAG-1: HSC70 binding. Thus, the contribution of decreased BAG-1 function to NSC71948-induced growth inhibition remains unclear.

In summary, we have developed a robust assay to identify inhibitors of the in vitro BAG-1:HSC70 interaction and have identified NSC71948/thioflavin S as a potential inhibitor of BAG-1 C-terminal protein-protein interactions. NSC71948 may be a useful tool to investigate the functional role of BAG-1 interactions. However, NSC71948 is a mixture of compounds (Kelenyi, 1967), and caution will be required in interpreting results from such studies because the selectivity profile of this compound is not fully known and off-target effects are possible. Clearly, NSC71948 is not an attractive starting point for medicinal chemistry, but further screens of additional libraries, especially those comprising more “drug-like” molecules, is warranted because inhibition of BAG-1 function may be an attractive strategy to reduce growth of BAG-1-overexpressing tumors.

Acknowledgments

We thank Prof. Carsten Carlberg (University of Kuopio, Finland) for (the DR3),tkLUC plasmid, the NCI-DTP for providing compounds, and Prof. Stefan Wiese (Ruhr-University, Bochum, Germany) for supplying wild-type and BAG-1-deficient MEFs.
References

Address correspondence to: Prof. Graham Packham, Cancer Research UK Centre, The Somers Cancer Sciences Building (MP824), Southampton General Hospital, Southampton, SO16 6YD, United Kingdom. E-mail G.K.Packham@soton.ac.uk

NSC71948 Inhibits BAG-1 Protein-Protein Interactions 689

Downloaded from jpet.aspetjournals.org at ASPET Journals on April 30, 2017